Seizert Capital Partners, LLC Biogen Inc. Transaction History

Seizert Capital Partners, LLC

$2.14 Billion
Q4 2024

A detailed history of Seizert Capital Partners, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Seizert Capital Partners, LLC holds 39,671 shares of BIIB stock, worth $5.49 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

39,671

Previous 11,004 260.51%

Holding current value

$5.49 Million

Previous $2.13 Million 184.39%

% of portfolio

0.28%

Previous 0.1%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$146.47 - $191.55 $4.2 Million - $5.49 Million	28,667 Added 260.51%	39,671 $6.07 Million
Q3 2024 Nov 06, 2024	BUY	$189.07 - $236.8 $646,241 - $809,382	3,418 Added 45.06%	11,004 $2.13 Million
Q2 2024 Aug 07, 2024	BUY	$190.52 - $236.72 $463,154 - $575,466	2,431 Added 47.16%	7,586 $1.76 Million
Q1 2024 May 01, 2024	SELL	$212.02 - $267.71 $25,230 - $31,857	-119 Reduced 2.26%	5,155 $1.11 Million
Q4 2023 Feb 07, 2024	BUY	$222.59 - $267.94 $28,046 - $33,760	126 Added 2.45%	5,274 $1.36 Million
Q3 2023 Nov 06, 2023	BUY	$253.3 - $285.89 $355,886 - $401,675	1,405 Added 37.54%	5,148 $1.32 Million
Q2 2023 Jul 27, 2023	SELL	$275.25 - $318.06 $107,347 - $124,043	-390 Reduced 9.44%	3,743 $1.07 Million
Q1 2023 May 09, 2023	BUY	$256.56 - $292.34 $164,198 - $187,097	640 Added 18.32%	4,133 $1.15 Million
Q4 2022 Jan 30, 2023	BUY	$252.44 - $306.72 $881,772 - $1.07 Million	3,493 New	3,493 $967,000
Q1 2022 May 03, 2022	SELL	$193.77 - $244.14 $4.16 Million - $5.24 Million	-21,464 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$223.92 - $287.77 $4.4 Million - $5.66 Million	19,655 Added 1086.51%	21,464 $5.15 Million
Q3 2021 Nov 03, 2021	SELL	$282.99 - $369.05 $18,111 - $23,619	-64 Reduced 3.42%	1,809 $512,000
Q2 2021 Aug 05, 2021	SELL	$259.0 - $414.71 $30.1 Million - $48.1 Million	-116,059 Reduced 98.41%	1,873 $649,000
Q1 2021 May 05, 2021	BUY	$242.95 - $284.63 $937,544 - $1.1 Million	3,859 Added 3.38%	117,932 $33 Million
Q4 2020 Feb 08, 2021	SELL	$236.26 - $355.63 $1.94 Million - $2.92 Million	-8,221 Reduced 6.72%	114,073 $27.9 Million
Q3 2020 Nov 03, 2020	BUY	$264.77 - $305.71 $51,365 - $59,307	194 Added 0.16%	122,294 $34.7 Million
Q2 2020 Aug 06, 2020	BUY	$258.66 - $342.55 $2.45 Million - $3.25 Million	9,482 Added 8.42%	122,100 $32.7 Million
Q1 2020 May 05, 2020	SELL	$268.85 - $341.04 $10.9 Million - $13.8 Million	-40,509 Reduced 26.45%	112,618 $35.6 Million
Q4 2019 Feb 10, 2020	SELL	$220.06 - $304.07 $8.66 Million - $12 Million	-39,358 Reduced 20.45%	153,127 $45.4 Million
Q3 2019 Nov 07, 2019	BUY	$217.44 - $243.88 $1.13 Million - $1.26 Million	5,174 Added 2.76%	192,485 $44.8 Million
Q2 2019 Aug 06, 2019	BUY	$219.29 - $241.72 $4.99 Million - $5.5 Million	22,764 Added 13.83%	187,311 $43.8 Million
Q1 2019 May 07, 2019	BUY	$216.71 - $338.96 $13.8 Million - $21.7 Million	63,895 Added 63.48%	164,547 $38.9 Million
Q4 2018 Feb 08, 2019	SELL	$278.5 - $352.75 $1.35 Million - $1.7 Million	-4,832 Reduced 4.58%	100,652 $30.3 Million
Q3 2018 Nov 09, 2018	BUY	$293.51 - $383.83 $2.03 Million - $2.66 Million	6,929 Added 7.03%	105,484 $37.3 Million
Q1 2018 May 10, 2018	BUY	$260.13 - $367.91 $14,307 - $20,235	55 Added 0.06%	98,555 $27 Million
Q4 2017 Feb 12, 2018	SELL	$307.64 - $344.58 $232,268 - $260,157	-755 Reduced 0.76%	98,500 $31.4 Million
Q3 2017 Oct 31, 2017	SELL	$281.15 - $329.69 $1.64 Million - $1.92 Million	-5,821 Reduced 5.54%	99,255 $31.1 Million
Q2 2017 Aug 09, 2017	BUY	N/A	105,076	105,076 $28.5 Million

Others Institutions Holding BIIB

# of Institutions

1,006

Shares Held

126M

Call Options Held

1.77M

Put Options Held

2.34M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $19.9B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seizert Capital Partners, LLC with notifications on news.

Account

Seizert Capital Partners, LLC Biogen Inc. Transaction History